Clinical Guide To DOTS Transfer Protocols: WHO Guidelines And Patient Care Continuity In 2026

Disambiguation Note: This clinical guide details the medical protocols for transferring Tuberculosis (TB) patients under the Directly Observed Treatment, Short-course (DOTS) framework. It does not refer to Polkadot (DOT) cryptocurrency transactions or Department of Transportation (DOT) licensing.

The execution of a seamless Directly Observed Treatment, Short-course (DOTS) transfer remains a cornerstone of global tuberculosis (TB) elimination strategies in 2026. Managed under strict World Health Organization (WHO) standards and National Tuberculosis Elimination Programs (NTEP), the DOTS transfer protocol ensures that patients undergoing therapy for drug-susceptible or drug-resistant TB can relocate geographically without interrupting their medication regimens.

Because tuberculosis treatment requires months of uninterrupted, daily multi-drug therapy, any gap in medicine administration risks treatment failure, disease relapse, and the selection of drug-resistant mycobacterial strains. A properly executed DOTS transfer protects both the individual patient and public health by maintaining a continuous, supervised chain of clinical custody.

The Clinical Necessity of Flawless DOTS Transfers

Tuberculosis therapy relies on strict adherence to prevent the selection of drug-resistant mutants. The standard treatment for drug-susceptible TB consists of a two-month intensive phase using Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol, followed by a four-month continuation phase of Isoniazid and Rifampicin. For drug-resistant TB (DR-TB), regimens in 2026 utilize newer shorter oral regimens lasting 6 to 9 months, containing Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin (BPaLM).

If a patient relocates during these long regimens without a formal transfer, several clinical hazards arise:

• Acquired Drug Resistance: Sub-therapeutic drug levels caused by missed doses allow Mycobacterium tuberculosis to mutate, transforming drug-susceptible infections into Multi-Drug Resistant (MDR-TB) or Extensively Drug-Resistant (XDR-TB) strains.
• Epidemiological Tracking Failures: Without formal transfers, patient outcomes are recorded as Lost-to-Follow-Up (LTFU) at the originating clinic. This distorts local epidemiological data and prevents national health registries from monitoring true treatment success rates.
• Public Health Transmission: Patients with interrupted therapy remain infectious for longer periods, continuing the cycle of transmission within their new communities.

Under the 2026 WHO End TB strategy benchmarks, national programs target a treatment success rate of over 90% and seek to reduce LTFU rates to under 5%. Achieving these metrics requires rigorous adherence to the clinical transfer pathway.

Standard Operating Procedures for the Three-Phase Transfer Workflow

The process of moving a active TB patient from one clinical jurisdiction to another is divided into three distinct operational phases. Each phase requires active communication, standardized record-keeping, and clinical verification.

Phase 1: Initiation and Documentation at the Sending Facility

When a patient notifies their healthcare provider of an impending relocation, the sending facility must act immediately. The clinical team must not wait for the patient to depart before starting the administrative process.

1. Address and Contact Verification: Obtain the exact physical address of the patient's new residence, including landmarks, local administrative districts, and postal codes. Collect multiple verified telephone numbers, including those of family members or close contacts.
2. Identify the Receiving Clinic: Utilize national TB program directories to locate the closest accredited DOTS center or health post to the patient's new address.
3. Prepare the Transfer Documentation: Complete three copies of the standardized DOTS Transfer Form.
4. Dispense Transit Medication: Provide the patient with a transit drug supply. In 2026, guidelines recommend dispensing a 7 to 14-day supply of their current regimen, depending on the travel duration, to prevent any gap in dosing before registration at the new facility.

Phase 2: Inter-Facility Communication and Secure Tracking

Relying solely on the patient to present their transfer papers at the new clinic is a primary point of failure. The sending facility must establish a direct line of communication with the receiving district.

1. Electronic Notification: Scan and transmit the DOTS Transfer Form via secure, encrypted national health information systems or dedicated TB registries.
2. Direct Contact: The sending clinic's TB coordinator must contact the receiving clinic's coordinator by phone or secure messaging to confirm receipt of the patient's clinical file and coordinate the expected arrival date.
3. Log "Transfer-Out" Status: In the originating clinic's TB Register, mark the patient's status as Transfer-Out (TO). This status remains provisional until final confirmation of arrival is received.

Phase 3: Registration, Clinical Intake, and Feedback Loop

Upon arrival at the destination, the receiving facility must rapidly integrate the patient back into supervised treatment.

1. Patient Intake Assessment: Verify the patient's identity, review the transfer form, assess the physical transit supply of medications, and perform a clinical evaluation.
2. Register as "Transfer-In": Record the patient in the receiving facility's TB register as Transfer-In (TI). Assign a new local registration number while cross-referencing their original national ID.
3. Complete the Feedback Loop: This is the most critical step for epidemiological integrity. The receiving clinician must complete the tear-off "Confirmation of Arrival" slip on the physical transfer form or update the digital national registry. This notification must be sent back to the originating clinic within 48 hours of intake, allowing the sending clinic to finalize the patient's status as a successfully completed transfer rather than a default.

Key Data Fields of the Standardized DOTS Transfer Form

The standardized transfer form acts as the legal and clinical passport for the patient's treatment. Clinical staff must complete every section with absolute accuracy.

• Demographic Details: Full legal name, date of birth, biological sex, current phone numbers, and emergency contact details.
• Clinical Diagnostic Profile: Anatomical site of disease (pulmonary versus extra-pulmonary), diagnostic methodology (smear microscopy, culture, or rapid molecular testing such as GeneXpert), and initial drug-resistance profile.
• Treatment History and Current Regimen: Date of original treatment initiation, the exact drug regimen and dosages, the cumulative number of doses administered to date, and categorization (e.g., New, Relapse, Treatment after Loss-to-Follow-Up).
• Adherence Logs: Documented confirmation of direct observation records, showing the exact date of the last supervised dose before transit.
• Administrative Routing: Name, code, and contact information of the sending clinic; name and code of the designated receiving clinic; and the printed name, signature, and credential of the transferring medical officer.

Comparing Patient Transitions: Referral vs. Transfer vs. Transit

To prevent administrative confusion within health systems, clinicians must distinguish between different types of patient movement. The clinical protocols, reporting requirements, and monitoring metrics differ significantly across these categories.

Clinical Troubleshooting: Managing Delayed Transfers and Lost-to-Follow-Up (LTFU)

When a transferred patient does not present at the receiving facility within the expected timeframe, immediate corrective action is mandatory. The clinical team must treat a delayed transfer as an active public health hazard.

Step-by-Step Recovery Protocol

If a patient fails to report within 3 days of their scheduled arrival date, the receiving facility's coordinator must notify the sending clinic. Both facilities must then launch a coordinated tracking effort:

1. Initiate Contact Tracing: Call all primary and secondary phone numbers provided on the transfer form. If local digital health tracking apps are utilized, check for recent location logins or adherence confirmations.
2. Deploy Community Health Workers: If the patient's new physical address is within reach, dispatch a community health worker or DOTS provider to conduct a home visit.
3. Verify Hospital Registries: Check local hospital admission logs and emergency room records to ensure the patient has not been hospitalized under a different department.
4. Register as Lost-to-Follow-Up (LTFU): If the patient cannot be located after 14 consecutive days of tracing, their status must be updated to LTFU in the registry, and local epidemiologists must be notified for advanced contact tracing.

Protocol for Handling Returned or Recovered Patients

When a patient is successfully traced after a treatment interruption, clinicians must follow standardized recovery steps:

Clinical Adherence Recovery Checklist

Conduct Sputum Re-evaluation: If the interruption lasted more than 14 consecutive days, perform a sputum smear microscopy and a rapid molecular drug susceptibility test (DST) to verify that the patient has not developed drug resistance during the gap.

Determine Regimen Adjustments: For short interruptions (under 14 days) with confirmed drug-susceptible status, resume the original regimen and extend the treatment end date to compensate for missed doses. For interruptions exceeding 30 days, re-classify the patient as Treatment After Loss-to-Follow-Up and initiate a complete clinical re-evaluation.

Reinforce Adherence Support: Enroll the patient in enhanced counseling or transition them to digital adherence technologies, such as video-supported therapy (VST) or electronic medication monitor boxes, to prevent future defaults.

Frequently Asked Questions About DOTS Transfer Protocols

What is the primary difference between a TB referral and a TB transfer?

A TB referral applies to a patient who has been diagnosed with tuberculosis but has not yet started treatment, requiring them to register and begin therapy at a new facility. A TB transfer applies to a patient who has already initiated an active course of TB treatment and must transition to a new facility to continue their regimen without interruption. Because transfer patients are already on active medication, they carry an established risk of developing drug resistance if their doses are interrupted, requiring formal "Transfer-Out" and "Transfer-In" tracking.

How many days of transit medication should a patient receive during a DOTS transfer?

Under standard clinical guidelines in 2026, patients should be provided with a 7 to 14-day supply of their current anti-TB regimen to cover their travel and registration period. Providing more than a 14-day supply is discouraged unless extreme transit distances are involved, as unsupervised self-administration increases the risk of poor adherence and delays registration at the receiving clinic.

What should a DOTS provider do if a transferred patient fails to report to the receiving clinic?

If a patient does not report within 3 days of their expected arrival, the receiving coordinator must immediately contact the sending facility to cross-verify contact information and begin phone tracing. If the patient remains unaccounted for after 24 to 48 hours of initial communication attempts, local community health workers must be deployed to the patient's newly listed physical address to perform an active home trace.

Can a drug-resistant TB (DR-TB) patient undergo a standard DOTS transfer?

Yes, but the transfer of a DR-TB patient requires direct coordination between specialized drug-resistant TB treatment centers and must utilize advanced infection control measures. The sending facility must ensure that the receiving clinic has an adequate stock of second-line medications (such as Bedaquiline or Linezolid) available before the patient departs, as these specialized drugs are not stocked at standard primary health posts.

How is a successful DOTS transfer confirmed in the national registry?

A transfer is only considered clinically and administratively successful when the sending facility receives the completed "Confirmation of Arrival" feedback slip (either physical or digital) from the receiving clinic. Until this feedback loop is completed, the patient's treatment outcome cannot be finalized, and they remain registered as a provisional transfer.

Secure Care Coordination for Tuberculosis Elimination

Maintaining strict clinical oversight during patient transitions is a non-negotiable component of tuberculosis care. By adhering to standardized DOTS transfer protocols, utilizing precise documentation, and closing the communication loop between health facilities, healthcare providers prevent treatment defaults and halt the rise of drug-resistant pathogens. Ensure your clinical team is trained on the latest 2026 guidelines, and actively track every transfer to safeguard individual patient health and wider community wellness.